Literature DB >> 3661586

How to classify Raynaud's phenomenon. Long-term follow-up study of 73 cases.

P Priollet1, M Vayssairat, E Housset.   

Abstract

Raynaud's phenomenon without an underlying cause was diagnosed in 96 consecutive patients in 1978 to 1979. Seventy-three patients were available for long-term follow-up. They were classified on initial evaluation as having primary Raynaud's phenomenon (49 patients) when no clinical, laboratory, or serologic abnormality was detected, and as having suspected secondary Raynaud's phenomenon when at least one finding was abnormal. Re-evaluation was performed in 1984 to 1985 after an average duration of Raynaud's phenomenon of 14.9 +/- 12 years. The average duration of the follow-up from initial to final evaluation was 4.7 +/- 1 years. On final evaluation, none of the 49 patients with an initial diagnosis of primary Raynaud's phenomenon had evidence of secondary Raynaud's phenomenon, whereas 14 of the 24 patients with suspected secondary Raynaud's phenomenon had a definite diagnosis. Among them, there were 13 connective tissue diseases. The study proved that Raynaud's phenomenon without an underlying cause must be followed up for more than two years, contrary to what was recommended previously, before it can be rightly diagnosed as primary Raynaud's phenomenon. Moreover, the results suggested that, in order to distinguish early primary Raynaud's phenomenon from suspected secondary Raynaud's phenomenon, a simple and noninvasive evaluation is sufficient. In this study, the evaluation included history and clinical examination, tests for antinuclear antibodies, radiography of hands, chest roentgenography, and nailfold capillary microscopy.

Entities:  

Mesh:

Year:  1987        PMID: 3661586     DOI: 10.1016/0002-9343(87)90760-1

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  8 in total

1.  Predictive value of nailfold capillaroscopy in the diagnosis of connective tissue diseases.

Authors:  D Blockmans; G Beyens; R Verhaeghe
Journal:  Clin Rheumatol       Date:  1996-03       Impact factor: 2.980

2.  Slow-releasing nicardipine in the treatment of Raynaud's phenomena without underlying diseases.

Authors:  C Ferri; R Cecchetti; G Cini; I Gambini; L La Civita; L Bernini; S Bombardieri; G Pasero
Journal:  Clin Rheumatol       Date:  1992-03       Impact factor: 2.980

3.  Remission of Raynaud's phenomenon after L-thyroxine therapy in a patient with hypothyroidism.

Authors:  A M Lateiwish; J Fehér; K Baraczka; K Rácz; R Kiss; E Gláz
Journal:  J Endocrinol Invest       Date:  1992-01       Impact factor: 4.256

Review 4.  Clinical aspects of systemic sclerosis (scleroderma).

Authors:  R M Silver
Journal:  Ann Rheum Dis       Date:  1991-11       Impact factor: 19.103

5.  Long-term follow-up study of 164 patients with definite systemic sclerosis: classification considerations.

Authors:  M Vayssairat; N Baudot; N Abuaf; C Johanet
Journal:  Clin Rheumatol       Date:  1992-09       Impact factor: 2.980

6.  Prognostic significance of nailfold capillary microscopy in patients with Raynaud's phenomenon and scleroderma-pattern abnormalities. A six-year follow-up study.

Authors:  P Zufferey; M Depairon; A M Chamot; M Monti
Journal:  Clin Rheumatol       Date:  1992-12       Impact factor: 2.980

Review 7.  Calcium channel blockers for primary Raynaud's phenomenon.

Authors:  Holly Ennis; Michael Hughes; Marina E Anderson; Jack Wilkinson; Ariane L Herrick
Journal:  Cochrane Database Syst Rev       Date:  2016-02-25

8.  Fludarabine Treatment of Patient with Chronic Lymphocytic Leukemia Induces a Digital Ischemia.

Authors:  Utku Erdem Soyaltin; Deniz Yuce Yildirim; Mustafa Yildirim; Mehmet Can Ugur; Ferhat Ekinci; Cengiz Ceylan; Harun Akar
Journal:  Case Rep Hematol       Date:  2016-11-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.